Jazz Pharmaceuticals plc Q4 2025 Earnings Call Summary

Achieved record annual revenue of $4.3 billion in 2025, driven by the successful launch of Modeyso and double-digit growth in the Xywav and Zepzelca franchises. Management is sharpening the corporate focus on rare disease, leveraging existing capabilities in sleep, epilepsy, and oncology to drive long-term value through internal R&D and M&A. Resolved significant legal headwinds by settling ANDA litigation for Epidiolex, extending the product's runway into the late 2030s, and settling the majority of r ...